Novel markers of cognitive impairment and resilience using digital and plasma biomarkers across different neurodegenerative diseases
Toniolo, S.; Zhao, S.; Broulidakis, M.; Gendarini, C.; Sinha, D.; Tahira, N.; Scholcz, A.; Amein, B.; Fower, A.; Van Duijn, C.; Thompson, S.; Manohar, S. G.; Koychev, I.; Husain, M.
Show abstract
Blood-based biomarkers enable early diagnosis of neurodegenerative diseases in a cost-effective and non-invasive way. Digital cognitive measures can capture early signs of cognitive impairment remotely and at scale. Their combination offers important opportunities for effective screening. We evaluated the performance of a new proteomic assay and a fully remote digital platform in a large memory clinic population (n = 391). Plasma biomarkers were measured using the NUcleic acid Linked Immuno-Sandwich Assay (NULISA) central nervous system panel. OCTAL (Oxford Cognitive Testing Portal) digital cognitive testing platform was used to measure cognition. Distinct proteomic patterns could be identified across different neurodegenerative diseases and associate with specific cognitive functions. Alzheimers Disease (e.g., pTau217), and novel proteomics biomarkers (e.g., ACHE and IL6R) were highly correlated with worse cognition. A cluster of biomarkers, including PRDX6, was overexpressed in healthy controls and associated with better cognition, indexing cognitive resilience.
Matching journals
The top 3 journals account for 50% of the predicted probability mass.
Similar papers in this journal
Similar papers in this journal
- Amyloid-associated increases in soluble tau is a key driver in accumulation of tau aggregates and cognitive decline in early Alzheimer 97%
- Plasma p-tau212: antemortem diagnostic performance and prediction of autopsy verification of Alzheimer’s disease neuropathology 97%
- Deep clinical phenotyping of Alzheimer’s Disease Patients Leveraging Electronic Medical Records Data Identifies Sex-Specific Clinical Associations 96%
Similar papers in this journal
- Deep Learning-Based Brain Transcriptomic Signatures Associated with the Neuropathological and Clinical Severity of Alzheimer's Disease 96%
- Polygenic coronary artery disease association with brain atrophy in the cognitively impaired 96%
- Tau accumulation and its spatial progression across the Alzheimer’s disease spectrum 95%